findmyKOL
Clinical trialNCT04340596Active, not recruitingPhase 1Interventional

Safety, Tolerability, and Efficacy of IL-15 Superagonist (N-803) With and Without Combination Broadly Neutralizing Antibodies to Induce HIV-1 Control During Analytic Treatment Interruption

SponsorNational Institute of Allergy and Infectious Diseases (NIAID)Enrollment118HIV Infection
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

14 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Alabama Crs (site Id# 31788)

    Birmingham, Alabama, United States

  • Ucla Care Center Crs

    Los Angeles, California, United States

  • Ucsd Antiviral Research Center Crs (site Id: 701)

    San Diego, California, United States

  • University of California, San Fransisco Hiv/aids Crs

    San Francisco, California, United States

  • Whitman-Walker Institute, Inc. Crs (site Id: 31791)

    Washington D.C., District of Columbia, United States

  • Northwestern University Crs

    Chicago, Illinois, United States

  • Massachusetts General Hospital Crs (mgh Crs) (site Id: 101)

    Boston, Massachusetts, United States

  • Washington University Therapeutics (wt) Crs

    St Louis, Missouri, United States

  • New Jersey Medical School Clinical Research Center Crs [site Id: 31786]

    Newark, New Jersey, United States

  • Columbia P&s Crs

    New York, New York, United States

  • Weill Cornell Uptown Crs (site Id: 7803)

    New York, New York, United States

  • Chapel Hill Crs (site Id: 3201)

    Chapel Hill, North Carolina, United States

  • Case Clinical Research Site

    Cleveland, Ohio, United States

  • Penn Therapeutics, Crs (site Id: 6201)

    Philadelphia, Pennsylvania, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
21 May 2021
Primary completion
30 Jun 2026
Completion
30 Dec 2026
Last update posted
25 Mar 2025
Registered enrollment
118
Registry id
NCT04340596

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.